Cogent Biosciences (COGT) to Release Quarterly Earnings on Tuesday

Key Points

• Cogent Biosciences is slated to announce its Q2 2025 earnings on August 5th, with analysts predicting a loss of ($0.54) per share for the quarter.
• The stock price of Cogent Biosciences opened at $12.09, with a market cap of $1.38 billion and a recent trading range between $3.72 and $12.97 over the past year.
• Institutional interest is increasing, with firms like AQR Capital Management and Goldman Sachs significantly boosting their stakes in Cogent Biosciences during Q1.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.54) per share for the quarter.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last released its earnings results on Tuesday, May 6th. The technology company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.04. On average, analysts expect Cogent Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Cogent Biosciences Stock Down 0.2%

NASDAQ:COGT traded down $0.02 during trading hours on Friday, reaching $11.40. 1,474,464 shares of the stock were exchanged, compared to its average volume of 4,799,851. The firm has a 50 day simple moving average of $8.62 and a 200-day simple moving average of $7.26. Cogent Biosciences has a 52 week low of $3.72 and a 52 week high of $12.97. The stock has a market capitalization of $1.30 billion, a P/E ratio of -6.20 and a beta of 0.35.

Insider Buying and Selling

In other Cogent Biosciences news, Director Fairmount Funds Management Llc bought 2,777,777 shares of the stock in a transaction that occurred on Thursday, July 10th. The shares were purchased at an average cost of $9.00 per share, for a total transaction of $24,999,993.00. Following the transaction, the director directly owned 9,003,418 shares in the company, valued at $81,030,762. The trade was a 44.62% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.29% of the stock is currently owned by corporate insiders.

Institutional Trading of Cogent Biosciences

Several large investors have recently added to or reduced their stakes in COGT. Strs Ohio acquired a new stake in Cogent Biosciences in the 1st quarter valued at approximately $36,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Cogent Biosciences by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,275 shares of the technology company's stock valued at $377,000 after acquiring an additional 3,693 shares during the period. Jane Street Group LLC increased its position in shares of Cogent Biosciences by 66.2% during the 1st quarter. Jane Street Group LLC now owns 123,822 shares of the technology company's stock valued at $742,000 after purchasing an additional 49,338 shares during the period. AQR Capital Management LLC increased its position in shares of Cogent Biosciences by 482.6% during the 1st quarter. AQR Capital Management LLC now owns 160,767 shares of the technology company's stock valued at $963,000 after purchasing an additional 133,174 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in shares of Cogent Biosciences by 14.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 988,962 shares of the technology company's stock valued at $5,924,000 after purchasing an additional 124,069 shares during the period.

Wall Street Analyst Weigh In

A number of research firms have commented on COGT. JPMorgan Chase & Co. increased their target price on Cogent Biosciences from $25.00 to $29.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. Citigroup increased their target price on Cogent Biosciences from $15.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, July 18th. Needham & Company LLC reaffirmed a "hold" rating on shares of Cogent Biosciences in a report on Tuesday, June 17th. Wedbush reaffirmed a "neutral" rating and set a $10.00 target price on shares of Cogent Biosciences in a report on Monday, June 30th. Finally, Guggenheim reissued a "buy" rating and issued a $17.00 price target on shares of Cogent Biosciences in a report on Tuesday, July 8th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $18.70.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.